Munk, Marion R.
Kurmann, Thomas
Márquez-Neila, Pablo
Zinkernagel, Martin S.
Wolf, Sebastian
Sznitman, Raphael
Funding for this research was provided by:
Innosuisse-Schweizerische Agentur für Innovationsförderung (# 6362.1 PFLS-LS)
Article History
Received: 22 September 2020
Accepted: 9 March 2021
First Online: 21 April 2021
Competing interests
: R.S. has received speaker fees from Bayer AG and is a shareholder of RetinAI Medical AG. M.R.M is a consultant for Zeiss, Bayer, Novartis and Lumithera. M.Z. is a consultant for Heidelberg, Bayer and Novartis. S.W. reports other from Bayer AG, other from Allergan, other from Novartis Pharma, other from Heidelberg Engineering, other from Zeiss, other from Chengdu Kanghong and other from Roche. The other authors declare no competing interests.